Market Overview

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

Related MDT
Benzinga's M&A Chatter for Tuesday August 26, 2014
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

Committed to researching treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting balloon is complete, with initial results expected in 2013.

The largest randomized controlled trial of its kind, IN.PACT DEEP is designed to assess the safety and efficacy of the IN.PACT Amphirion drug-eluting balloon as a treatment for one of the most severe forms of peripheral artery disease -- critical limb ischemia that occurs below the knee.

Posted-In: News FDA

 

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters